Casimersen is an investigational intravenously administered antisense oligonucleotide proposed for the treatment of Duchenne muscular dystrophy (DMD) in patients who have a confirmed mutation of the DMD gene that is amenable to exon 45 skipping.

If you have a Hayes login, click here to view the full report on the Knowledge Center.